Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report

Abstract

This case report emphasizes the importance of long-term follow-up and initial surgical treatment of low-grade ESS and suggests systemic hormonal therapy in case of recurrence.

Cystic, Nodular and Cavitary Metastases to the Lungs in a Patient with Endometrial Stromal Sarcoma of the Uterus

“…During this time, no new metastatic lesions have been identified. Consistent with the findings of previous reports (12)(13)(14)(15)(16), MPA therapy should be the firstline therapy for pulmonary metastases of low-grade ESS.…”

“…However, several case reports have been published regarding the efficacy of progesterone and aromatase inhibitors in the treatment of metastatic low-grade ESS (12)(13)(14)(15)(16), and the guidelines for uterine neoplasms proposed by the Japan Society of Gynecologic Oncology recommend the use of hormonal therapy, including progesterone and aromatase inhibitors, in cases of recurrent low-grade ESS (17). For such patients, the median overall survival from recurrence is 41 to 62 months (12)(13)(14)(15)(16). Our patient has responded very well to MPA therapy, tolerating the treatment well with no adverse events for approximately five years.…”

Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature

“…The prognosis for low-grade ESS is extremely good, with a 5-year survival rate of >90% (6). However, 40-50% of those individuals with low-grade ESS develop recurrent disease, which often occurs 10-20 years after the initial diagnosis (17,18).…”

“…Table I shows the patient characteristics and treatment outcomes of those individuals with low-grade ESS who were treated with aromatase inhibitors (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). The age of the patients at the time of starting aromatase inhibitor treatment ranged from 28 to 87 years (mean age, 53 years).…”

Endometrial sarcoma. Case report and review of the literature

“…Hormone therapy include: a) megestrol/medroxyprogesterone, gonadotrophin releasing hormone analogues and aromatase inhibitors, like letrazole and anastrozole. Spano JP et al [6] and Alkasi et al [7], are 2 case reports which shows 10 year free survival rate for the patients that received aromatase inhibitor for 10 years. Chu et al [8], study compared the outcome for the patients who received adjuvant megestrol 160mg/day with those who didn't.…”